Filtered By:
Specialty: Hematology
Condition: von Willebrand Disease

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 77 results found since Jan 2013.

Targeting von Willebrand Factor in Ischaemic Stroke: Focus on Clinical Evidence.
Abstract Despite great efforts in stroke research, disability and recurrence rates in ischaemic stroke remain unacceptably high. To address this issue, one potential target for novel therapeutics is the glycoprotein von Willebrand factor (vWF), which increases in thrombogenicity especially under high shear rates as it bridges between vascular sub-endothelial collagen and platelets. The rationale for vWF as a potential target in stroke comes from four bodies of evidence. (1) Animal models which recapitulate the pathogenesis of stroke and validate the concept of targeting vWF for stroke prevention and the use of the...
Source: Thrombosis and Haemostasis - May 31, 2018 Category: Hematology Authors: Buchtele N, Schwameis M, Gilbert JC, Schörgenhofer C, Jilma B Tags: Thromb Haemost Source Type: research

Vascular Proteomics Reveals Critical Roles of ADAMTS18 in Stroke Associated with Imbalanced Level of Von Willebrand Factor Versus ADAMTS13
Conclusion and Significance-Results of this first vascular proteomic study of Adamts18 KO mice establish a substantial new resource for investigation of how ADAMTS gene affects cellular phenotypes of stroke. These new findings contribute to inform novel prevention strategies and direct therapeutic development for stroke.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Zhu, R., Pan, Y.-H., Lu, T., Dang, S., Liao, C.-C., Zhang, W. Tags: 301. Vascular Wall Biology, Endothelial Progenitor Cells, and Platelet Adhesion, Activation, and Biochemistry: Poster III Source Type: research

Low ADAMTS13 activity is associated with an increased risk of ischemic stroke
ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin motif repeats 13) has antithrombotic properties because it cleaves von Willebrand factor (VWF) in smaller, less active multimers. The aim of our study was to investigate prospectively the association between ADAMTS13 activity and ischemic stroke. We included 5941 individuals ≥55 years without a history of stroke or transient ischemic attack (TIA) of the Rotterdam Study, a population-based cohort study. ADAMTS13 activity was measured at inclusion with the FRETS-VWF73 assay and VWF antigen (VWF:Ag) levels by enzyme-linked immunosorbent assay. We assessed ...
Source: Blood - December 17, 2015 Category: Hematology Authors: Sonneveld, M. A. H., de Maat, M. P. M., Portegies, M. L. P., Kavousi, M., Hofman, A., Turecek, P. L., Rottensteiner, H., Scheiflinger, F., Koudstaal, P. J., Ikram, M. A., Leebeek, F. W. G. Tags: Free Research Articles, Thrombosis and Hemostasis, Clinical Trials and Observations Source Type: research

Lack of secondary microthrombosis after thrombin-induced stroke in mice and non-human primates.
CONCLUSIONS: Our data demonstrates that secondary microthrombosis does not occur after thrombin-induced stroke. In view of that, the pathophysiological roles of hematologic players promoting or protecting from secondary microthrombosis (such as Factor XII, von Willebrand Factor, T-cells…) deserve to be reevaluated in non-TMVO stroke models. This article is protected by copyright. All rights reserved. PMID: 24354644 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - December 16, 2013 Category: Hematology Authors: Gauberti M, de Lizarrondo SM, Orset C, Vivien D Tags: J Thromb Haemost Source Type: research

Lack of secondary microthrombosis after thrombin‐induced stroke in mice and non‐human primates
ConclusionsOur data demonstrates that secondary microthrombosis does not occur after thrombin‐induced stroke. In view of that, the pathophysiological roles of hematologic players promoting or protecting from secondary microthrombosis (such as Factor XII, von Willebrand Factor, T‐cells…) deserve to be reevaluated in non‐TMVO stroke models.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - December 16, 2013 Category: Hematology Authors: Maxime Gauberti, Sara Martinez Lizarrondo, Cyrille Orset, Denis Vivien Tags: Brief Report ‐ Vascular Biology Source Type: research

The VWF-GPIb axis in ischaemic stroke: lessons from animal models.
Abstract Stroke is a leading cause of death and long-term disability worldwide. Ischaemic stroke is caused by a blood clot that obstructs cerebral blood flow. Current treatment mainly consists of achieving fast reperfusion, either via pharmacological thrombolysis using tissue plasminogen activator or via endovascular thrombectomy. Unfortunately, reperfusion therapy is only available to a limited group of patients and reperfusion injury can further aggravate brain damage. Hence, there is an urgent need for better understanding of ischaemic stroke pathophysiology in order to develop novel therapeutic strategies. In ...
Source: Thrombosis and Haemostasis - March 30, 2016 Category: Hematology Authors: Denorme F, De Meyer SF Tags: Thromb Haemost Source Type: research

The von Willebrand Factor A1 domain mediates thromboinflammation, aggravating ischemic stroke outcome in mice.
In conclusion, our data identify a potential role for VWF in the recruitment of proinflammatory monocytes, neutrophils and T-cells to the ischemic brain via a mechanism that is mediated by its A1 domain. PMID: 32107335 [PubMed - as supplied by publisher]
Source: Haematologica - February 26, 2020 Category: Hematology Authors: Denorme F, Martinod K, Vandenbulcke A, Denis CV, Lenting PJ, Deckmyn H, Vanhoorelbeke K, De Meyer SF Tags: Haematologica Source Type: research

Paradoxical Increase of Stroke in Patients with Defect of High Molecular Weight Multimers of the von Willebrand Factors following Transcatheter Aortic Valve Replacement.
CONCLUSION:  MLBCs and CT-ADP > 180 seconds were identified as predictors for ischemic stroke or TIA. The present study suggests that the defects of HMW multimers of the VWFs may contribute not only to bleeding events but also to thrombotic events. PMID: 32726854 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - July 28, 2020 Category: Hematology Authors: Matsushita K, Marchandot B, Trimaille A, Kibler M, Heger J, Peillex M, Hess S, Grunebaum L, Reydel A, Kindo M, Hoang MT, Sato C, De Poli F, Leddet P, Ohana M, Jesel L, Ohlmann P, Susen S, Morel O Tags: Thromb Haemost Source Type: research

Haemostatic biomarkers are associated with long-term recurrent vascular events after ischaemic stroke.
In conclusion, plasma levels of haemostatic factors were associated with vascular death and coronary events, but not with recurrent stroke. Our results suggest that the predictive value of biomarkers differ by specific outcome measure and subgroup of patients. PMID: 27357914 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - June 29, 2016 Category: Hematology Authors: Pedersen A, Redfors P, Lundberg L, Gils A, Declerck PJ, Nilsson S, Jood K, Jern C Tags: Thromb Haemost Source Type: research

Structural analysis of ischemic stroke thrombi: histological indications for therapy resistance.
Abstract Ischemic stroke is caused by a thromboembolic occlusion of cerebral arteries. Treatment is focused on fast and efficient removal of the occluding thrombus, either via intravenous thrombolysis or via endovascular thrombectomy. Recanalization, however, is not always successful and factors contributing to failure are not completely understood. Although the occluding thrombus is the primary target of acute treatment, little is known about its internal organization and composition. The aim of this study, therefore, was to better understand the internal organization of ischemic stroke thrombi on a molecular and...
Source: Haematologica - May 1, 2019 Category: Hematology Authors: Staessens S, Denorme F, François O, Desender L, Dewaele T, Vanacker P, Deckmyn H, Vanhoorelbeke K, Andersson T, De Meyer SF Tags: Haematologica Source Type: research

ADAMTS13-mediated thrombolysis of t-PA-resistant occlusions in ischemic stroke in mice
Rapid vascular recanalization forms the basis for successful treatment of cerebral ischemia. Currently, tissue plasminogen activator (t-PA) is the only approved thrombolytic drug for ischemic stroke. However, t-PA does not always result in efficient thrombus dissolution and subsequent blood vessel recanalization. To better understand thrombus composition, we analyzed thrombi retrieved from ischemic stroke patients and found a distinct presence of von Willebrand factor (VWF) in various samples. Thrombi contained on average 20.3% ± 10.1% VWF, and this was inversely correlated with thrombus red blood cell content. We h...
Source: Blood - May 11, 2016 Category: Hematology Authors: Denorme, F., Langhauser, F., Desender, L., Vandenbulcke, A., Rottensteiner, H., Plaimauer, B., Francois, O., Andersson, T., Deckmyn, H., Scheiflinger, F., Kleinschnitz, C., Vanhoorelbeke, K., De Meyer, S. F. Tags: Thrombosis and Hemostasis Source Type: research

Thrombolytic strategies for ischemic stroke in the thrombectomy era
J Thromb Haemost. 2021 Apr 9. doi: 10.1111/jth.15336. Online ahead of print.ABSTRACTTwenty-five years ago, intravenous thrombolysis has revolutionized the care of patients with acute ischemic stroke. Since 2015, randomized clinical trials have demonstrated that mechanical thrombectomy improves functional outcome in stroke patients over intravenous thrombolysis alone. More recently, three randomized clinical trials have suggested that mechanical thrombectomy alone is non-inferior to a combined strategy with both intravenous thrombolysis and mechanical thrombectomy. In the present review, we will present the last clinical an...
Source: Thrombosis and Haemostasis - April 9, 2021 Category: Hematology Authors: Maxime Gauberti Sara Martinez de Lizarrondo Denis Vivien Source Type: research

Coagulation biomarkers for ischemic stroke
We report on coagulation biomarker-induced risk of IS, stroke severity, and outcomes following IS derived from prospective population studies, case-control studies, and acute-phase IS studies. We found indications that many coagulation and inflammation biomarkers are associated with IS, but it is early to conclude that any of these biomarkers can be applied in a therapeutic setting to predict patients at risk of IS, stroke severity at the acute phase, and clinical outcome after treatment. The strongest evidence for a role in IS was found for beta-thromboglobulin, von Willebrand factor, factor VIII, fibrinogen, thrombin-act...
Source: Thrombosis and Haemostasis - June 5, 2023 Category: Hematology Authors: Aarazo Barakzie A J Gerard Jansen Hugo Ten Cate Moniek P M de Maat Source Type: research